16 Geographic Atrophy Clinical Trials in Orlando, FL (2026)

Q: How do I join a clinical trial in Orlando?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Orlando research site will contact you.

Recruiting Geographic Atrophy Studies in Orlando

NCT06841354Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sac...

Orlando, FL1,000 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07218926Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) w...

Orlando, FL450 participantsGlaxoSmithKline

View Study Details

NCT07043400Recruiting

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line the...

Orlando, FL351 participantsBeiGene

View Study Details

NCT06659445Recruiting

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

The purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of ONL1204 and 2 treatment frequencies in patients wi...

Orlando, FL324 participantsONL Therapeutics

View Study Details

NCT06719141Recruiting

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and...

Orlando, FL320 participantsLongboard Pharmaceuticals

View Study Details

NCT05066217Recruiting

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult p...

Orlando, FL260 participantsEpygenix

View Study Details

NCT05219617Recruiting

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in ped...

Orlando, FL252 participantsSK Life Science, Inc.

View Study Details

NCT06990269Recruiting

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assess...

Orlando, FL240 participantsADARx Pharmaceuticals, Inc.

View Study Details

NCT04411823Recruiting

Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction

Researchers are trying to identify predictors for gastroesophageal reflux disease after sleeve gastrectomy....

Orlando, FL200 participantsMayo Clinic

View Study Details

NCT06628310Recruiting

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is gi...

Orlando, FL180 participantsAbbVie

View Study Details

NCT07015424Recruiting

Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass

The goal of this clinical trial is to evaluate weight loss with TORe and intensive lifestyle modification versus intensive lifestyle modification alone in subjects who have regained weight following a...

Orlando, FL108 participantsBoston Scientific Corporation

View Study Details

NCT06999187Recruiting

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refra...

Orlando, FL96 participantsDren Bio

View Study Details

NCT06128018Recruiting

Comparing Endoscopic Ultrasound vs Surgical Gastrojejunostomy for Management of GOO.

The goal of this interventional study is to learn about the outcomes between two options for the management of malignant gastric outlet obstruction....

Orlando, FL70 participantsAdventHealth

View Study Details

NCT07541287Recruiting

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JAD...

Orlando, FL30 participantsJade Biosciences, Inc.

View Study Details

NCT06797518Recruiting

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. T...

Orlando, FL20 participantsNovartis Pharmaceuticals

View Study Details

NCT07054684Recruiting

Study of BHV-1400 in IgA Nephropathy

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN)....

Orlando, FL20 participantsBiohaven Therapeutics Ltd.

View Study Details

About Geographic Atrophy Clinical Trials in Orlando

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 16 geographic atrophy clinical trials recruiting participants in Orlando, FL. These studies are seeking a combined 3,921 participants. Research is being sponsored by Merck Sharp & Dohme LLC, GlaxoSmithKline, BeiGene and 13 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Orlando — FAQ

Are there geographic atrophy clinical trials in Orlando?

Yes, there are 16 geographic atrophy clinical trials currently recruiting in Orlando, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Orlando?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Orlando research site will contact you about next steps.

Are clinical trials in Orlando free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Orlando studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 16 active trials in Orlando are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated July 13, 2026 from ClinicalTrials.gov